Trending Investment Opportunities
Advertisement
- Statera Biopharma Inc STAB signed a binding Memorandum of Understanding with Holobeam Technologies Inc.
- Holobeam offers holographic medical imaging and therapeutic technologies for early cancer detection, treatment, and other diseases using Holographic Energy Teleportation (HET) technology.
- Under the terms of the MOU, Statera will acquire a 25% interest in Holobeam for access to their technology and assist in targeting Statera drugs specifically to the site of cancer in concentrations that would not be possible under normal dosing.
- The MOU provides an exclusivity period of sixty (60) days for negotiating and finalizing a definitive agreement.
- Michael Handley, President & Chief Executive Officer of Statera, said, "Holobeam's technology also has the potential to precisely deliver focused energy to the tumor cells, thus making them more susceptible to therapeutic intervention."
- In April, Statera Biopharma entered into a non-binding term sheet with Immune Therapeutics Inc IMUN to sell its naltrexone and met-enkephalin rights.
- Under the anticipated terms, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics.
- Price Action: STAB shares are down 13.50% at $0.19 during the premarket session on the last check Tuesday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.